Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study
Titel:
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study
Auteur:
Harding, James J Fan, Jia Oh, Do-Youn Choi, Hye Jin Kim, Jin Won Chang, Heung-Moon Bao, Lequn Sun, Hui-Chuan Macarulla, Teresa Xie, Feng Metges, Jean-Phillippe Ying, Jie'er Bridgewater, John Lee, Myung-Ah Tejani, Mohamedtaki A Chen, Emerson Y Kim, Dong Uk Wasan, Harpreet Ducreux, Michel Bao, Yuanyuan Boyken, Lisa Ma, Jiafang Garfin, Phillip Pant, Shubham